5,543
Views
17
CrossRef citations to date
0
Altmetric
Editorials

Clinical management of dilated cardiomyopathy: current knowledge and future perspectives

, , , , &
Pages 137-140 | Received 04 Oct 2015, Accepted 24 Nov 2015, Published online: 14 Dec 2015

References

  • Papers of special note have been highlighted as:
  • *of interest
  • **of considerable interest
  • Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270–276.

** Updated classification of the cardiomyopathies of the European Society of Cardiology.

  • Merlo M, Pivetta A, Pinamonti B, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail. 2014;16:317–324.

** Study on large and well selected population Focused on natural history in DCM.

  • Merlo M, Sinagra G, Carniel E, et al. Poor prognosis of rare sarcomeric gene variants in patients with dilated cardiomyopathy. Clin Transl Sci. 2013;6:424–428.

* Focus on rare sarcomeric gene variants in Dilated Cardiomyopathy. Patients with DCM carrying rare variants in sarcomeric genes manifest a poorer prognosis as compared to noncarriers after the age of 50 years.

  • Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531–547.

** State of the art regarding the Dilated Cardiom-yopathy.

  • Arbustini E, Narula N, Dec GW, et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. Glob Heart. 2013;8:355–382.

* New proposal for the classification of cardiom-yopathies.

  • Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807–1816.

** Statement on the Classification of the cardiomyopathies of the American Heart Association.

  • Moretti M, Merlo M, Barbati G, et al. Prognostic impact of familial screening in dilated cardiomyopathy. Eur J Heart Fail. 2010;12:922–927.
  • Aleksova A, Barbati G, Merlo M, et al. Deleterious impact of mild anemia on survival of young adult patients (age 45 ± 14 years) with idiopathic dilated cardiomyopathy: data from the Trieste Cardiomyopathies Registry. Heart Lung. 2011;40:454–461.
  • Lapu-Bula R, Robert A, De Kock M, et al. Risk stratification in patients with dilated cardiomyopathy: contribution of Doppler-derived left ventricular filling. Am J Cardiol. 1998;82:779–785.
  • Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404–1413.
  • Aleksova A, Carriere C, Zecchin M, et al. New-onset left bundle branch block independently predicts long-term mortality in patients with idiopathic dilated cardiomyopathy: data from the Trieste Heart Muscle Disease Registry. Europace. 2014;16:1450–1459.
  • Merlo M, Pyxaras SA, Pinamonti B, et al. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol. 2011;57:1468–1476.

** Prevalence and prognostic role of left ventricular reverse remodeling in idiopathic dilated cardiom-yopathy.

  • Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324:98–102.
  • Kyriakides ZS, Manolis AG, Kolettis TM. The effects of ventricular asynchrony on myocardial perfusion. Int J Cardiol. 2007;119:3–9.
  • Harmon WG, Sleeper LA, Cuniberti L, et al. Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry). Am J Cardiol. 2009;104:281–286.
  • Zecchin M, Merlo M, Pivetta A, et al. How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with ‘SCD-HeFT criteria?’. Am J Cardiol. 2012;109:729–735.
  • Itoh M, Shinke T, Yoshida A, et al. Reduction in coronary microvascular resistance through cardiac resynchronization and its impact on chronic reverse remodelling of left ventricle in patients with non-ischaemic cardiomyopathy. Europace. 2015;17:1407–1414.
  • Stolfo D, Tonet E, Barbati G, et al. Acute hemodynamic response to cardiac resynchronization in dilated cardiomyopathy: effect on late mitral regurgitation. Pacing Clin Electrophysiol. 2015;38:1287–1296.
  • Deng XU, Xia KE, Chen PO, et al. Reversion of left ventricle remodeling in spontaneously hypertensive rats by valsartan is associated with the inhibition of caspase-3, −8 and −9 activities. Biomed Rep. 2015;3:533–536.
  • Tseliou E, Reich H, De Couto G, et al. Cardiospheres reverse adverse remodeling in chronic rat myocardial infarction: roles of soluble endoglin and Tgf-beta signaling. Basic Res Cardiol. 2014;109:443.
  • Merlo M, Stolfo D, Anzini M, et al. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist? J Am Heart Assoc. 2015;4:e001504.

** Study on persistent or apparent healing phenomenon in patients with Dilated Cardiomyopathy receiving optimal medical treatment.

  • McMurray JJ, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

** Pivotal trial of newly developed drug LCZ696 in the setting of Heart Failure.

  • Nakano SJ, Miyamoto SD, Movsesian M, et al. Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy. Circ Heart Fail. 2015;8:57–63.
  • Kelkar AA, Butler J, Schelbert EB, et al. Mechanisms contributing to the progression of ischemic and nonischemic dilated cardiomyopathy: possible modulating effects of paracrine activities of stem cells. J Am Coll Cardiol. 2015;66:2038–2047.
  • Woitek F, Zentilin L, Hoffman NE, et al. Intracoronary cytoprotective gene therapy: a study of VEGF-B167 in a pre-clinical animal model of dilated cardiomyopathy. J Am Coll Cardiol. 2015;66:139–153.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.